Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Merck
Baxter
McKinsey
McKesson

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ACETAMINOPHEN; ASPIRIN; CAFFEINE

See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Acetaminophen; Aspirin; Caffeine

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT04132336 Study to Find Out the Optimal Dose of Caffeine in the Combination Tablet of Naproxen Sodium and Caffeine in Patients Experiencing Moderate to Severe Pain After Having Wisdom Teeth Removed Not yet recruiting Bayer Phase 2 2019-10-29 The researchers in this study want to find out the optimal dose of Caffeine in the combination tablet of Naproxen Sodium and Caffeine that works in patients experiencing moderate to severe pain after having wisdom teeth removed. In the US, Naproxen has been marketed since 1976, and Naproxen Sodium has been approved for over-the-counter (OTC) use since 1994 for the temporary relief of minor aches and pains. Caffeine, which is generally consumed as coffee, tea or cocoa, has been shown to enhance the effectiveness of various pain relievers, and therefore is accepted as an additive to painkillers like aspirin and acetaminophen. Patients participating in this study will undergo a surgery to remove 3 or 4 wisdom teeth. If the pain severity after the surgery meets the study requirement, patients will receive oral tablet(s) of Naproxen Sodium and Caffeine, or Naproxen Sodium, or Caffeine, or placebo (drug with no active ingredient). Patients can also receive additional pain medication when needed. Researchers will also learn if the patients have any medical problems during the study.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Acetaminophen; Aspirin; Caffeine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00471952 Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache Completed Merck Sharp & Dohme Corp. Phase 3 2007-04-01 The purpose of this study is to evaluate the effect of rizatriptan, alone or combined with caffeine for treating acute attacks of migraine. Each subject will have 3 months to treat 3 acute migraine headache attacks. Each subject will be dispensed one box containing 3 packets of study medication labeled for Headache #1, Headache #2, or Headache #3. Each packet wil contain either Maxalt 10mg MLT or a Maxalt placebo (sugar pill), and a capsule containing either caffeine 75mg or a capsule containing placebo (sugar). One headache will be treated with a combination of Maxalt 10mg MLT and caffeine. Another headache will be treated with a combination of Maxalt 10mg MLT and a capsule containing placebo. A third headache will be treated with just placebo. Neither the subject, the study coordinator, or your study doctor will know in which order you will receive the three different treatments. This information is available in case of emergency.
NCT00471952 Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache Completed Diamond Headache Clinic Phase 3 2007-04-01 The purpose of this study is to evaluate the effect of rizatriptan, alone or combined with caffeine for treating acute attacks of migraine. Each subject will have 3 months to treat 3 acute migraine headache attacks. Each subject will be dispensed one box containing 3 packets of study medication labeled for Headache #1, Headache #2, or Headache #3. Each packet wil contain either Maxalt 10mg MLT or a Maxalt placebo (sugar pill), and a capsule containing either caffeine 75mg or a capsule containing placebo (sugar). One headache will be treated with a combination of Maxalt 10mg MLT and caffeine. Another headache will be treated with a combination of Maxalt 10mg MLT and a capsule containing placebo. A third headache will be treated with just placebo. Neither the subject, the study coordinator, or your study doctor will know in which order you will receive the three different treatments. This information is available in case of emergency.
NCT01080677 Caffeine/Propranolol Acute Migraine Completed Stanford University Phase 2 2007-01-01 This is a research study to assess the safety of caffeine/propranolol at different dose levels. We want to find out what effects, good and/or bad, it has on patients and their migraines.
NCT01248468 Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine Completed Novartis Phase 4 2010-11-01 The main purpose of this study is to compare the efficacy and safety of aspirin, acetaminophen and caffeine (AAC) with sumatriptan and placebo in the acute treatment of migraine.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Acetaminophen; Aspirin; Caffeine

Condition Name

Condition Name for Acetaminophen; Aspirin; Caffeine
Intervention Trials
Mechanical Low Back Pain 1
Pain, Migraine 1
Migraine Without Aura 1
Migraine With Aura 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Acetaminophen; Aspirin; Caffeine
Intervention Trials
Migraine Disorders 5
Headache 2
Pain, Postoperative 1
Low Back Pain 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Acetaminophen; Aspirin; Caffeine

Trials by Country

Trials by Country for Acetaminophen; Aspirin; Caffeine
Location Trials
United States 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Acetaminophen; Aspirin; Caffeine
Location Trials
California 2
Illinois 2
Ohio 1
North Carolina 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Acetaminophen; Aspirin; Caffeine

Clinical Trial Phase

Clinical Trial Phase for Acetaminophen; Aspirin; Caffeine
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Acetaminophen; Aspirin; Caffeine
Clinical Trial Phase Trials
Completed 3
Not yet recruiting 3
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Acetaminophen; Aspirin; Caffeine

Sponsor Name

Sponsor Name for Acetaminophen; Aspirin; Caffeine
Sponsor Trials
Diamond Headache Clinic 1
Bayer 1
Merck Sharp & Dohme Corp. 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Acetaminophen; Aspirin; Caffeine
Sponsor Trials
Industry 5
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Dow
Johnson and Johnson
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.